中国医院用药评价与分析2016，Vol.16Issue(1)：48-53,6.DOI:10.14009/j.issn.1672-2124.2016.01.020
那格列奈对照瑞格列奈治疗2型糖尿病疗效与安全性的Meta分析
Meta-analysis on Efficacy and Safety for Control Study of Nateglinide and Repaglinide in Type 2 Diabetes Mellitus
摘要
Abstract
OBJECTIVE:To evaluate the efficacy and safety of control study on nateglinide and repaglinide in type 2 diabetes mellitus.METHODS:the related literature from Pubmed, Medline, Cochrane, CNKI, Wanfang database and VIP database was retrieved , the quality of the selected literature was evaluated and Meta-analysis was conducted on the data of 26 RCTs that accorded with requirements.RESULTS:After treatment, the HbA1c and the fasting blood glucose (FBG) were significantly decreased compared with before treatment , the difference was statistically significant by self-comparison in two groups (P<0.05).To compare the drop difference between two groups before and after treatment:the difference of HbA1c [MD=0.17, 95%CI=(-0.06,0.41),P=0.15] and 2 hour postprandial blood glucose [MD=0.05,95%CI=(-0.36, 0.46), P=0.80] had no statistical significance between 2 groups.There was statistical significance in the drop difference of FBG between 2 groups, and repaglinide group was better than nateglinide group [MD=0.41, 95%CI=(0.08, 0.74), P=0.01];The incidence of ADR had no statistical significance [ OR =0.93, 95%CI =( 0.68, 1.28 ), P =0.67 ]. CONCLUSIONS:The curative effects of nateglinide is exact , safe and well tolerated .关键词
那格列奈/瑞格列奈/2型糖尿病/Meta分析Key words
Nateglinide/Repaglinide/Type 2 diabetes mellitus/Meta-analysis分类
医药卫生引用本文复制引用
李义秀,徐睿来,章新晶,梁佳,谢珊珊..那格列奈对照瑞格列奈治疗2型糖尿病疗效与安全性的Meta分析[J].中国医院用药评价与分析,2016,16(1):48-53,6.基金项目
中国药学会"十二五科技支撑计划"课题(NO.2013BAI06B04Y023090) （NO.2013BAI06B04Y023090）
